Aligos Therapeutics Announces Executive and Director Changes
Ticker: ALGS · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Aligos Therapeutics is shuffling execs and directors, with changes to pay packages.
AI Summary
Aligos Therapeutics, Inc. announced on January 30, 2025, changes in its board and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to the compensatory arrangements for its key executives.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in executive and director roles, especially if numerous or sudden, can indicate internal challenges or strategic realignments that may pose risks.
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- January 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- One Corporate Dr., 2nd Floor (address) — Principal executive offices
- South San Francisco, CA 94080 (address) — Principal executive offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors but does not specify the exact roles affected in this section.
Who are the newly elected directors?
The filing states that directors have been elected but does not name the individuals in this particular section.
What are the details of the compensatory arrangements for certain officers?
The filing mentions adjustments to compensatory arrangements for certain officers but does not provide specific details within this report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 30, 2025.
What is the primary business of Aligos Therapeutics, Inc. according to the filing?
According to the filing, Aligos Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances).
Filing Stats: 636 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-02-03 16:02:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
Filing Documents
- d860038d8k.htm (8-K) — 25KB
- 0001193125-25-019256.txt ( ) — 148KB
- algs-20250130.xsd (EX-101.SCH) — 3KB
- algs-20250130_lab.xml (EX-101.LAB) — 18KB
- algs-20250130_pre.xml (EX-101.PRE) — 11KB
- d860038d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: February 3, 2025 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Operating Officer & Chief Financial Officer